Visit the ACCC COVID-19 Resource Center & Listserv for Insights on Providing Optimal Patient Care During the Pandemic.
 

Share

    


In This Section

Home / Blurb / Discussion List

FDA Approves Daratumumab in Combination for Frontline Multiple Myeloma

Sep 26, 2019, 15:29 PM
URL:
On September 26, 2019, the U.S. Food and Drug Administration (FDA)  approved daratumumab (Darzalex, Janssen) for adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant (ASCT).

Read FDA announcement.

Posted 9/26/2019

Leave a comment